GO:0031895 V1B vasopressin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031895 (V1B vasopressin receptor binding) is a molecular function defined as binding to a V1B vasopressin receptor (AVPR1B).
• The V1B receptor (AVPR1B) is a G protein-coupled receptor that binds arginine vasopressin (AVP) and is highly expressed in the anterior pituitary, where it regulates ACTH secretion [5,6].
• V1B receptor binding is a key step in the hypothalamic-pituitary-adrenal (HPA) axis stress response, and its expression is regulated by stress and glucocorticoids [6,7].
• The V1B receptor is also expressed in extrapituitary tissues, including the brain, kidney, and adrenal gland, where it mediates diverse physiological effects.
• Dysregulation of V1B receptor binding has been implicated in stress-related disorders, depression, and cancer progression [3,5].
• Studying V1B vasopressin receptor binding requires integrated structural, pharmacological, and genetic approaches, including CRISPR-based models [3,5].
Description
GO:0031895, V1B vasopressin receptor binding, is a molecular function term that describes the binding of a ligand to the V1B vasopressin receptor (AVPR1B). The V1B receptor is a member of the vasopressin receptor family, which includes V1A, V1B, and V2 receptors, all of which are G protein-coupled receptors (GPCRs) that mediate the actions of arginine vasopressin (AVP). Among these, the V1B receptor is unique in its prominent expression in the anterior pituitary corticotrophs, where it stimulates adrenocorticotropic hormone (ACTH) release and plays a central role in the hypothalamic-pituitary-adrenal (HPA) axis stress response [5,6]. The binding of AVP to the V1B receptor is the initiating event for this signaling cascade, making GO:0031895 a critical molecular function for understanding neuroendocrine regulation [6,7]. Beyond the pituitary, the V1B receptor is expressed in the brain, kidney, and other tissues, where it modulates behaviors, fluid balance, and cellular proliferation. The receptor's involvement in stress-related disorders, depression, and cancer has made it a target of intense pharmacological and structural research [3,5]. Recent molecular dynamics simulations have provided detailed insights into antagonist binding to the V1B receptor, revealing distinct binding modes that could inform drug design. Understanding the molecular basis of V1B vasopressin receptor binding is therefore essential for both basic neurobiology and therapeutic development.
V1B vasopressin receptor binding At A Glance
| GO ID | GO:0031895 |
|---|---|
| GO term | V1B vasopressin receptor binding |
| Ontology | molecular_function |
| Synonym | V1B vasopressin receptor ligand |
| Major function | Binding to the V1B vasopressin receptor (AVPR1B), initiating or modulating receptor-mediated signaling. |
| Receptor family | Vasopressin receptor family (GPCR, class A) |
| Primary ligand | Arginine vasopressin (AVP) |
| Tissue expression | Anterior pituitary, brain, kidney, adrenal gland |
| Associated diseases | Stress-related disorders, depression, cancer |
What Is GO:0031895?
The Gene Ontology term GO:0031895, V1B vasopressin receptor binding, is defined as the binding to a V1B vasopressin receptor. This molecular function encompasses the interaction between a ligand (such as arginine vasopressin or a synthetic agonist/antagonist) and the V1B receptor protein (AVPR1B). It is a binding activity that occurs at the receptor's orthosteric site and is a prerequisite for receptor activation or inhibition. The term is classified under molecular_function in the Gene Ontology and has the synonym V1B vasopressin receptor ligand.
Why Is V1B vasopressin receptor binding Important in Cell Biology?
V1B vasopressin receptor binding is important because it is the molecular trigger for a wide range of physiological and pathological processes. In the anterior pituitary, AVP binding to the V1B receptor stimulates ACTH secretion, which is essential for the HPA axis stress response [5,6]. Dysregulation of this binding has been linked to stress-related disorders, depression, and anxiety [3,5]. In extrapituitary tissues, V1B receptor binding influences social behavior, memory, and cell proliferation. Moreover, the V1B receptor is a therapeutic target for conditions such as Cushing's disease, and understanding its binding properties is crucial for drug development. The recent structural characterization of antagonist binding to the V1B receptor has opened new avenues for designing selective modulators.
• Regulates ACTH secretion and the HPA axis stress response [5,6].
• Implicated in stress-related disorders, depression, and anxiety [3,5].
• Expressed in extrapituitary tissues, influencing behavior and fluid balance.
• A target for pharmacological intervention in Cushing's disease and other endocrine disorders.
• Plays a role in cell proliferation and cancer progression.
• Binding properties are critical for drug design and selectivity.
• Provides a model for understanding GPCR-ligand interactions [3,5].
• Its regulation by stress and glucocorticoids is well-documented [6,7].
• Contributes to the diversity of vasopressin receptor functions.
• Offers insights into neuroendocrine and behavioral regulation.
Molecular Mechanism of V1B vasopressin receptor binding
Ligand recognition and binding pocket
In simple terms: The V1B receptor has a specific pocket where vasopressin or drugs can dock.
The V1B vasopressin receptor (AVPR1B) is a class A G protein-coupled receptor with a seven-transmembrane domain architecture. The binding pocket for arginine vasopressin (AVP) and synthetic ligands is formed by residues in the transmembrane helices and extracellular loops. Molecular dynamics simulations have revealed that antagonist binding to the V1B receptor involves distinct conformational states and interactions with key residues, providing a structural basis for ligand selectivity. This binding is the first step in receptor activation or blockade.
Conformational changes upon binding
In simple terms: When a ligand binds, the receptor changes shape to transmit a signal inside the cell.
Ligand binding to the V1B receptor induces conformational changes that propagate from the orthosteric site to the intracellular face, enabling coupling to G proteins, primarily Gq/11. These changes are essential for downstream signaling, including phospholipase C activation and calcium mobilization. Structural studies of related vasopressin receptors, such as V2, have elucidated similar activation mechanisms, and molecular dynamics simulations of V1B have highlighted the dynamic nature of these transitions [3,4].
G protein coupling and signaling
In simple terms: The receptor activates G proteins, which then trigger a cascade of cellular responses.
Upon AVP binding, the V1B receptor acts as a guanine nucleotide exchange factor for Gq/11, leading to activation of phospholipase C, production of inositol trisphosphate and diacylglycerol, and release of intracellular calcium. This signaling cascade ultimately stimulates ACTH secretion in pituitary corticotrophs [5,6]. The specificity of G protein coupling is determined by the receptor's intracellular domains and is modulated by ligand efficacy.
Regulation of receptor availability
In simple terms: Cells can adjust how many receptors are on their surface, affecting how strongly they respond.
The availability of V1B receptors at the cell surface is regulated by multiple mechanisms, including transcriptional control, mRNA stability, and receptor trafficking. Stress and glucocorticoids have been shown to modulate V1B receptor mRNA levels in the anterior pituitary, thereby altering the sensitivity of the HPA axis [6,7]. Extrapituitary expression of the V1B receptor is also developmentally and tissue-specifically regulated.
Pharmacological modulation
In simple terms: Drugs can block or mimic vasopressin's binding to the V1B receptor.
Selective antagonists and agonists of the V1B receptor have been developed for research and therapeutic purposes. Molecular dynamics simulations have provided insights into how antagonists such as SSR149415 bind to the V1B receptor, revealing key interactions that stabilize the inactive state. These findings are critical for the design of drugs targeting stress-related disorders and other conditions linked to V1B receptor signaling.
Key Genes Involved in GO:0031895 V1B vasopressin receptor binding
The following genes and proteins are central to V1B vasopressin receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AVPR1B | Encodes the V1B vasopressin receptor, the direct binding target | Primary gene for studying GO:0031895; mutations affect binding and signaling |
| AVP | Encodes arginine vasopressin, the endogenous ligand | Ligand for V1B receptor; regulates binding affinity and efficacy |
| AVPR1A | Encodes the V1A vasopressin receptor, a related subtype | Comparative studies of receptor selectivity and binding |
| AVPR2 | Encodes the V2 vasopressin receptor, another subtype | Structural and pharmacological comparisons; target of tolvaptan |
| GNAQ | Encodes Gq alpha subunit, mediates V1B signaling | Downstream effector of V1B receptor binding |
| GNA11 | Encodes G11 alpha subunit, alternative Gq/11 partner | Contributes to V1B receptor signaling diversity |
| PLCB1 | Phospholipase C beta 1, downstream of Gq/11 | Mediates calcium signaling upon V1B activation |
| POMC | Pro-opiomelanocortin, precursor of ACTH | Regulated by V1B receptor binding in pituitary |
| CRH | Corticotropin-releasing hormone, upstream regulator | Modulates V1B receptor expression and HPA axis |
| CRHR1 | CRH receptor type 1, co-regulates ACTH release | Interacts with V1B signaling in stress response |
| NR3C1 | Glucocorticoid receptor, feedback regulator | Regulates V1B receptor mRNA levels |
| FKBP5 | Co-chaperone of glucocorticoid receptor | Modulates glucocorticoid feedback on V1B receptor |
| BDNF | Brain-derived neurotrophic factor, neuroplasticity | Linked to V1B receptor effects on behavior |
| OXTR | Oxytocin receptor, related neuropeptide receptor | Comparative binding and behavioral studies |
| TRPV1 | Transient receptor potential vanilloid 1 | Potential crosstalk in sensory neurons |
| MAPK1 | Mitogen-activated protein kinase 1 | Downstream signaling of V1B receptor |
| MAPK3 | Mitogen-activated protein kinase 3 | Downstream signaling of V1B receptor |
| CREB1 | cAMP response element-binding protein | Transcription factor activated by V1B signaling |
How Is V1B vasopressin receptor binding Regulated?
The expression and function of the V1B vasopressin receptor are regulated at multiple levels. In the anterior pituitary, V1B receptor mRNA levels are modulated by stress and glucocorticoids, with adrenalectomy increasing and glucocorticoid treatment decreasing receptor expression [6,7]. This feedback regulation is critical for maintaining HPA axis homeostasis. Additionally, the receptor undergoes desensitization and internalization upon prolonged agonist exposure, a process mediated by G protein-coupled receptor kinases and arrestins. Extrapituitary expression is regulated in a tissue-specific manner, suggesting distinct transcriptional control mechanisms. The binding affinity of the receptor can also be influenced by post-translational modifications and interacting proteins, although these mechanisms are less well characterized for V1B compared to other vasopressin receptors.
V1B vasopressin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AVPR1B | Depression, anxiety, HPA axis dysregulation | AVPR1B knockout mouse; CRISPR point mutation in binding pocket |
| AVPR1B | Cushing's disease | Pituitary tumor cell lines with AVPR1B overexpression or knockout |
| AVP | Stress-related disorders | AVP knockout or knock-in models with altered binding affinity |
| AVPR1B | Cancer cell proliferation | Cancer cell lines with AVPR1B knockout or overexpression |
| NR3C1 | Glucocorticoid feedback resistance | CRISPR knock-in of NR3C1 mutations in pituitary cells |
Stress-related disorders and depression
Dysregulation of V1B vasopressin receptor binding has been implicated in stress-related disorders, including depression and anxiety. Chronic stress alters V1B receptor expression in the pituitary and brain, leading to HPA axis hyperactivity, a hallmark of major depressive disorder [3,5]. Antagonists of the V1B receptor have shown antidepressant-like effects in preclinical models, highlighting the therapeutic potential of targeting this binding interaction.
Cushing's disease and endocrine tumors
In Cushing's disease, excessive ACTH secretion from pituitary adenomas is often driven by increased V1B receptor signaling. The binding of AVP to the V1B receptor stimulates ACTH release, contributing to hypercortisolism [5,6]. Targeting the V1B receptor with antagonists is a promising therapeutic strategy for Cushing's disease, and structural insights into antagonist binding are guiding drug development.
Cancer
Emerging evidence suggests that V1B vasopressin receptor binding plays a role in cancer progression. The receptor is expressed in various tumors, where it can promote cell proliferation and survival. Molecular dynamics studies of antagonist binding to the V1B receptor provide a basis for developing anticancer agents that block these effects.
From V1B vasopressin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of AVPR1B knockout on stress response? | AVPR1B knockout mouse or CRISPR knockout in pituitary cell lines |
| How do point mutations in the AVPR1B binding pocket affect ligand affinity? | CRISPR point mutation knock-in in cell lines |
| Can a tagged AVPR1B be used to track receptor trafficking? | Knock-in of fluorescent or epitope tag at the AVPR1B locus |
| What is the effect of AVPR1B overexpression on ACTH secretion? | Overexpression of AVPR1B in AtT-20 cells |
| How does AVPR1B binding regulate gene expression? | CRISPR knockout followed by RNA-seq |
| Can CRISPR library screening identify modifiers of V1B signaling? | Genome-wide CRISPR knockout library in pituitary cells |
How to Study the V1B vasopressin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Binding affinity (Kd, Ki) and receptor density (Bmax) | Characterizing V1B receptor ligands |
| Molecular dynamics simulation | Ligand-receptor interactions and conformational changes | Structural basis of antagonist binding |
| CRISPR knockout | Loss-of-function effects on V1B signaling | Identifying genes required for receptor function |
| RNA-seq | Transcriptional changes upon receptor modulation | Downstream signaling networks |
| Proteomics | Protein expression and interactions | Identifying receptor complexes |
| Immunohistochemistry | Tissue distribution of V1B receptor | Mapping expression in brain and pituitary |
| Calcium imaging | Intracellular calcium mobilization | Functional assessment of receptor activation |
| ACTH secretion assay | Hormone release from pituitary cells | Physiological readout of V1B receptor binding |
Ligand binding assays
Radioligand binding assays using tritiated AVP or selective antagonists are the gold standard for measuring V1B vasopressin receptor binding affinity and kinetics. These assays can be performed on membrane preparations from cells expressing recombinant AVPR1B or on native tissues such as the anterior pituitary [5,6]. Competition binding experiments with unlabeled ligands allow determination of Ki values and receptor selectivity.
Molecular dynamics simulations
Molecular dynamics simulations provide atomic-level insights into the binding of agonists and antagonists to the V1B receptor. These computational methods have been used to reveal distinct binding modes for antagonists and to identify key residues involved in ligand recognition. Such simulations complement experimental structural biology and can guide drug design.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate V1B receptor binding and signaling. For example, a screen in pituitary cells could uncover regulators of AVPR1B expression or downstream signaling. These screens are powerful for discovering novel therapeutic targets.
Transcriptional and proteomic profiling
RNA-seq and proteomics can be used to assess changes in gene expression and protein abundance following manipulation of V1B receptor binding. For instance, knockout of AVPR1B in pituitary cells followed by RNA-seq can reveal downstream transcriptional networks. Proteomic approaches can identify interacting proteins and post-translational modifications of the receptor [6,7].
How CRISPR Can Be Used to Study GO:0031895 V1B vasopressin receptor binding
Knockout
CRISPR knockout of AVPR1B can be used to eliminate V1B vasopressin receptor binding and study its physiological consequences. For example, AVPR1B knockout mice exhibit altered stress responses and reduced ACTH secretion [5,6]. In cell culture, knockout of AVPR1B in pituitary cell lines can confirm the specificity of ligand binding and signaling. EDITGENE provides custom AVPR1B knockout cell models to facilitate such studies.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions in the AVPR1B binding pocket to dissect the molecular determinants of ligand binding. For instance, mutations in transmembrane residues identified by molecular dynamics simulations can be validated experimentally. EDITGENE offers precise point mutation services to create such models.
Knock-in
Knock-in of tags or reporter genes at the AVPR1B locus allows real-time tracking of receptor expression, trafficking, and localization. Fluorescent tags such as GFP or epitope tags like HA can be inserted using CRISPR. These models are valuable for imaging studies and for isolating receptor complexes. EDITGENE provides tagged knock-in cell lines for AVPR1B and related genes.
Overexpression
Overexpression of AVPR1B in cell lines that normally lack the receptor can create a gain-of-function system to study binding and signaling in isolation. This approach is useful for pharmacological profiling of agonists and antagonists. EDITGENE offers stable overexpression cell lines for AVPR1B and its variants.
How EDITGENE Supports V1B vasopressin receptor binding Research
Researchers studying V1B vasopressin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for V1B vasopressin receptor binding research.
Frequently Asked Questions About V1B vasopressin receptor binding
What is GO:0031895?
GO:0031895 is the Gene Ontology term for V1B vasopressin receptor binding, defined as binding to a V1B vasopressin receptor (AVPR1B).
What genes are involved in V1B vasopressin receptor binding?
The primary gene is AVPR1B, which encodes the V1B receptor. The ligand is encoded by AVP. Other related genes include AVPR1A, AVPR2, and downstream signaling molecules like GNAQ [5,8].
Where is the V1B vasopressin receptor expressed?
It is highly expressed in the anterior pituitary and also found in the brain, kidney, and adrenal gland [6,8].
What is the function of V1B vasopressin receptor binding?
It mediates arginine vasopressin signaling, leading to ACTH secretion, stress response regulation, and various extrapituitary effects [5,6].
How is V1B vasopressin receptor binding studied?
Common methods include radioligand binding assays, molecular dynamics simulations, CRISPR knockout, and RNA-seq [3,5].
What diseases are associated with V1B vasopressin receptor binding?
Stress-related disorders, depression, Cushing's disease, and cancer have been linked to V1B receptor function [3,5].
Can CRISPR be used to study V1B vasopressin receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting receptor function.
What are the synonyms for GO:0031895?
The synonym is V1B vasopressin receptor ligand.
How does stress affect V1B receptor binding?
Stress and glucocorticoids regulate V1B receptor mRNA levels, thereby modulating binding capacity and HPA axis sensitivity [6,7].
What is the role of V1B receptor in the brain?
In the brain, V1B receptor binding influences social behavior, memory, and stress-related behaviors.
Conclusion
GO:0031895, V1B vasopressin receptor binding, is a fundamental molecular function that governs the interaction between arginine vasopressin and its receptor AVPR1B. This binding event is critical for neuroendocrine regulation, stress responses, and various physiological processes. Dysregulation of this interaction is implicated in depression, Cushing's disease, and cancer, making it a valuable therapeutic target. Advances in structural biology and CRISPR-based models continue to unravel the molecular details of V1B receptor binding, offering new opportunities for drug discovery and personalized medicine.
References
- 3. Ślusarz MJ. 2025. Structural Basis for Antagonist Binding to Vasopressin V1b Receptor Revealed by the Molecular Dynamics Simulations.. Biopolymers 116(1):e23627 PMID: 39286992
- 4. Fouillen A et al.. 2025. Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.. Nat Commun 16(1):3899 PMID: 40274867
- 5. Birnbaumer M. 2000. Vasopressin receptors.. Trends Endocrinol Metab 11(10):406-10 PMID: 11091117
- 6. Aguilera G et al.. 2000. Regulation of vasopressin V1b receptors in the anterior pituitary gland of the rat.. Exp Physiol 85 Spec No:19S-26S PMID: 10795903
- 7. Rabadan-Diehl C et al.. 1995. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat.. J Neuroendocrinol 7(12):903-10 PMID: 8745267
- 8. Lolait SJ et al.. 1995. Extrapituitary expression of the rat V1b vasopressin receptor gene.. Proc Natl Acad Sci U S A 92(15):6783-7 PMID: 7624319
